[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-356476-105":59,"doc-detail-356476-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","ubiquitin-mediated-stabilization-of-kdm5b-drives-chemoresistance-via-repression-of-dual-specificity-phosphatase-4-in-ovarian-cancer","Ubiquitin-mediated stabilization of KDM5B drives chemoresistance via repression of dual-specificity phosphatase 4 in ovarian cancer","","Platinum-based chemotherapy remains central to first-line treatment for ovarian cancer, yet acquired resistance limits survival and progression outcomes. This study identifies abnormal overexpression of histone lysine demethylase 5B (KDM5B) as a strong correlate of cisplatin resistance and tumor progression. Genome-wide analysis shows KDM5B removes H3K4me3 at the DUSP4 promoter to activate the MAPK pathway. KDM5B stability is regulated by the ubiquitin-proteasome system via USP7, FBXW7, and HIPK1, and dual targeting resensitizes tumors while repressing disease progression.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/ubiquitin-mediated-stabilization-of-kdm5b-drives-chemoresistance-via-repression-of-dual-specificity-phosphatase-4-in-ovarian-cancer/356476/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/ubiquitin-mediated-stabilization-of-kdm5b-drives-chemoresistance-via-repression-of-dual-specificity-phosphatase-4-in-ovarian-cancer/356476.png","ImageObject",300,407,{"name":92,"@type":93},"Genevieve","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-19","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What links KDM5B to cisplatin resistance in ovarian cancer?","Question",{"text":112,"@type":113},"Abnormal overexpression of KDM5B correlates with cisplatin resistance and ovarian cancer progression. KDM5B promotes resistance by removing H3K4me3 at the DUSP4 promoter, activating the MAPK pathway.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does the paper describe DUSP4’s role in signaling?",{"text":117,"@type":113},"DUSP4 is presented as a negative regulator of the MAPK pathway that dephosphorylates MAP kinases such as ERK1/2, JNK, and p38. Downregulation of DUSP4 via KDM5B is linked to chemoresistance in ovarian cancer.",{"name":119,"@type":110,"acceptedAnswer":120},"Which proteins are implicated in regulating KDM5B stability?",{"text":121,"@type":113},"KDM5B stability is described as controlled through the ubiquitin-proteasome system mediated by USP7, FBXW7, and HIPK1. Depleting KDM5B and USP7 resensitizes ovarian cancer to cisplatin.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},356476,1790190306,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1374391974585,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Signal Transduction [and Targeted Therapy](and Targeted Therapy www.nature.com/sigtrans)[ www.nature.com/sigtrans](and Targeted Therapy www.nature.com/sigtrans)  \nUbiquitin-mediated stabilization of KDM5B drives chemoresistance via repression of dual-speciﬁcity phosphatase 4 in ovarian cancer  \nJung Yoo1, Go Woon Kim1, Yu Hyun Jeon 1, Jaewook Kim1, Enzhi Luo1, Sang Wu Lee 1, Soo Yeon Oh1, Junjeong Choi1, Kuglae Kim1 and So Hee Kwon 1 ✉  \n\n|  | Despite advances in therapeutic regimens for managing cancer progression, ovarian cancer (OVC) still depends on platinum-based chemotherapy as its ﬁrst-line treatment. Acquired resistance is accompanied by abnormal alterations in epigenetic regulation; however, in-depth mechanistic studies on cisplatin-resistant OVC are lacking. Herein, we show that abnormal overexpression of histone lysine demethylase 5B (KDM5B), but not KDM5A, strongly correlates with cisplatin resistance and OVC tumor progression. Genome-wide sequencing data revealed that KDM5B removes H3K4me3 from the promoter of dual-speciﬁcity phosphatase 4 (DUSP4), activating the MAPK pathway to increase cisplatin resistance. We also found that KDM5B protein stability is dynamically controlled via the ubiquitin-proteasome system (UPS), which is mediated by ubiquitin-speciﬁc protease 7 (USP7), F-box and WD repeat domain-containing 7 (FBXW7), and homeodomain-interacting protein kinase 1 (HIPK1) . KDM5B and USP7 depletion effectively resensitizes OVC to cisplatin resistance, whereas DUSP4 silencing results in resistance in vitro and in vivo. Targeting KDM5B and USP7 synergistically represses tumor progression and increases sensitivity to cisplatin. Overall, we propose two new UPS-associated proteins, USP7 and FBXW7, which are responsible for abnormal KDM5B protein regulation, and suggest a novel |  |\n| --- | --- | --- |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| mechanism to overcome cisplatin resistance in OVC by targeting the KDM5B–DUSP4 axis. |  |  |\n|  | Signal Transduction and Targeted Therapy (2026)11:89 ; [https://doi.org/10.1038/s41392-026-02601-y](https://doi.org/10.1038/s41392-026-02601-y) |  |\n|  |  |  |\n\nINTRODUCTION  \nOvarian cancer (OVC) ranks as the third most common gynecological malignancy worldwide, but it remains the most lethal.1 Approximately 75% of OVC patients are diagnosed at advanced FIGO stage III or IV, often with distant metastases.2,3 The current standard of care for OVC patients includes optimal cytoreductive surgery followed by platinum-based chemotherapy. Up to 80% of OVC patients initially respond to platinum-based chemotherapy, but approximately 70% of responders develop platinum resistance and relapse.4 Many therapeutic regimens and clinical trials are aimed at overcoming and treating platinum-resistant OVC via combinations of different chemotherapeutic modalities.5–8 Nonetheless, resistance to platinum-based drugs such as cisplatin remains a formidable barrier to improving overall survival (OS;\u003C12 months) and progression-free survival (PFS; \u003C4 months) .3,4 Therefore, understanding the mechanisms of drug resistance in OVC is crucial for identifying reliable biomarkers that may predict patients’ responses to therapies and improve treatment outcomes.  \nRecent studies have increased our understanding of how deregulation of epigenetic factors and abnormal alterations in the chromatin landscape contribute to drug resistance in OVC. For example, abnormal overexpression of histone deacetylases is positively correlated with cisplatin resistance in OVC cell lines.9 Similarly, the overexpression of the histone lysine methyltransferase EZH2 has also been found to contribute to acquired cisplatin resistance in OVC.10 Among the various epigenetic regulators, the  \nhistone lysine demethylase 5 (KDM5) protein family, primarily KDM5A and KDM5B, has gained increasing attention in the context of tumorigenesis and chemoresistance in differ","cbCaiuAKZJiJZwXJ","https://ap.wps.com/l/cbCaiuAKZJiJZwXJ","pdf",8837532,21,"English","# Introduction\n## Platinum-based chemotherapy and ovarian cancer resistance\n## Epigenetic dysregulation and KDM5 involvement\n## DUSP4 and MAPK pathway context","[{\"question\":\"What links KDM5B to cisplatin resistance in ovarian cancer?\",\"answer\":\"Abnormal overexpression of KDM5B correlates with cisplatin resistance and ovarian cancer progression. KDM5B promotes resistance by removing H3K4me3 at the DUSP4 promoter, activating the MAPK pathway.\"},{\"question\":\"How does the paper describe DUSP4’s role in signaling?\",\"answer\":\"DUSP4 is presented as a negative regulator of the MAPK pathway that dephosphorylates MAP kinases such as ERK1/2, JNK, and p38. Downregulation of DUSP4 via KDM5B is linked to chemoresistance in ovarian cancer.\"},{\"question\":\"Which proteins are implicated in regulating KDM5B stability?\",\"answer\":\"KDM5B stability is described as controlled through the ubiquitin-proteasome system mediated by USP7, FBXW7, and HIPK1. Depleting KDM5B and USP7 resensitizes ovarian cancer to cisplatin.\"}]","Ubiquitin-mediated stabilization of KDM5B drives chemoresistance via repression of dual-specificity phosphatase 4 in ovarian cancer | PDF",1790125507,53,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1a575b9427b1a6382fbcf7b5c32c949b.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ecb10349304b2842be9e15848f75704f.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/abdceaed3519ac0d0dc533dbd7186977.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9e1d82c545b5008b40c97129471249b8.webp",980,1301]